Oncolytics Biotech (ONCY) 1.01 $ONCY Oncolytics
Post# of 64074
Posted On: 03/04/2015 6:37:30 PM
Oncolytics Biotech (ONCY) 1.01 $ONCY
Oncolytics' Reolysin Gets Orphan Drug Status Yet Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 1:38PM CST
Oncolytics' (ONCY) lead candidate Reolysin gets orphan drug status for primary peritoneal cancer.
CYTK: 7.95 (-0.02), ONCY: 1.01 (-0.15), CBM: 33.97 (+0.02), THRX: 19.64 (+0.08)
Premarket Gainers / Losers as of 9:10 em
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 8:13AM CST
BV: 6.41 (-2.67), AMRN: 1.69 (+0.15), PHMD: 1.98 (+0.15), BOBE: 46.36 (-13.28), NVGN: 3.36 (+0.85), EFUT: 4.70 (+0.57), TNET: 33.93 (-3.95), ATOS: 2.03 (+0.07), FAST: 39.82 (-1.28), W: 28.90 (+3.65), TIVO: 11.55 (+0.30), CYCC: 1.10 (-0.32), ANF: 20.27 (-3.72), CYTX: 1.14 (-0.06), AEO: 15.96 (+1.14), AMBA: 67.49 (+4.44), CRMD: 6.16 (+0.66), ONCY: 1.01 (-0.15), EXAS: 21.90 (+0.84), ATHM: 42.61 (+4.21), SOL: 1.43 (+0.08), VEEV: 25.72 (-6.97), OREX: 8.49 (+0.85), NURO: 1.78 (+0.03), ACHN: 11.63 (-0.51), CNDO: 3.23 (+0.44), SWHC: 14.34 (+1.29), IFON: 2.71 (+1.01)
Nasdaq stocks posting largest volume increases
AP - Tue Mar 03, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OREX: 8.49 (+0.85), GDEF: 10.38 (-0.02), WBB: 17.22 (-0.03), ONCY: 1.01 (-0.15), CYCC: 1.10 (-0.32), DRAM: 3.29 (+0.34), AXPW: 0.23 (-0.01), CMLS: 3.13 (-0.18), SQBK: 25.74 (+0.08), MITL: 9.56 (+0.20), TSRI: 5.07 (-0.21), MBLX: 0.97 (-0.08)
Most active Nasdaq-traded stocks
AP - Tue Mar 03, 5:06PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 16.59 (-0.22), OREX: 8.49 (+0.85), MU: 29.26 (-0.40), ONCY: 1.01 (-0.15), FB: 80.89 (+1.29), ARCP: 10.10 (+0.02), ZNGA: 2.39 (+0.04), MSFT: 43.05 (-0.23), INTC: 34.12 (+0.02), AAPL: 128.54 (-0.82), CSCO: 29.33 (-0.21)
Another Orphan Drug tag for Oncolytics' Reolysin
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 6:48AM CST
ONCY: 1.01 (-0.15)
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Primary Peritoneal Cancer
CNW Group - Tue Mar 03, 5:30AM CST
Oncolytics Biotech(®) Inc. ("Oncolytics"
(TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN(®), for the treatment of primary peritoneal cancers. The designation was granted on the basis of the Company's December 2014 application for an Orphan Drug Designation encompassing ovarian, fallopian tube and primary peritoneal cancers which are generally treated as one indication. On February 11, 2015, the Company announced that it had received Orphan Drug Designation for ovarian cancer and for cancers of the fallopian tube on March 2, 2015.
ONCY: 1.01 (-0.15), ONC.TO: 1.26 (-0.18)
Oncolytics Biotech heads north on new Orphan Drug tag for Reolysin
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 12:44PM CST
ONCY: 1.01 (-0.15)
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Cancer of the Fallopian Tube
CNW Group - Mon Mar 02, 5:30AM CST
Oncolytics Biotech(®) Inc. ("Oncolytics" (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN(®), for the treatment of cancer of the fallopian tube. The designation was granted on the basis of the Company's December 2014 application for an Orphan Drug Designation encompassing ovarian, fallopian tube and primary peritoneal cancers which are generally treated as one indication. On February 11, 2015, the Company announced that it had received Orphan Drug Designation for ovarian cancer.
ONCY: 1.01 (-0.15), ONC.TO: 1.26 (-0.18)
Oncolytics Biotech Completes Enrolment for Reolysin Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 19, 11:10AM CST
Oncolytics Biotech Inc. (ONCY) completed enrolment in a phase II study on its lead candidate, Reolysin, in patients suffering from advanced or metastatic colorectal cancer.
LCI: 62.28 (+0.01), ONCY: 1.01 (-0.15), SLXP: 157.13 (+0.63), SCMP: 14.82 (-0.15)
Traders smitten with tiny thinly-traded biotechs
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 9:44AM CST
GENE: 5.75 (+0.39), HTBX: 6.45 (-0.18), SGNL: 2.89 (+0.20), ROSG: 3.35 (unch), TTPH: 38.50 (-0.82), ONCY: 1.01 (-0.15), CLRX: 1.27 (-0.05), MELA: 1.82 (-0.01), AKAO: 10.42 (-0.33), WGBS: 4.80 (-0.05), EGRX: 37.72 (+1.03)
Oncolytics' Reolysin Gets Another Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 3:08PM CST
Oncolytics' (ONCY) lead candidate Reolysin gets orphan drug status for pancreatic cancer.
IPXL: 40.40 (+0.47), BMRN: 109.79 (+1.43), ONCY: 1.01 (-0.15), CBM: 33.97 (+0.02)
Oncolytics Bio completes enrollment in Canadian cancer trial
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 11:45AM CST
ONCY: 1.01 (-0.15)
Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Colorectal Cancer Study
CNW Group - Wed Feb 18, 5:30AM CST
Oncolytics Biotech(®) Inc. ("Oncolytics" (TSX:ONC, NASDAQ:ONCY) today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN(® )in patients with advanced or metastatic colorectal cancer (IND 210). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
ONCY: 1.01 (-0.15), ONC.TO: 1.26 (-0.18)
Oncolytics Bio's lead product an Orphan Drug for pancreatic cancer
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 1:04PM CST
ONCY: 1.01 (-0.15)
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Pancreatic Cancer
PR Newswire - Tue Feb 17, 5:30AM CST
Oncolytics Biotech® Inc. ("Oncolytics" (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.
ONCY: 1.01 (-0.15), ONC.TO: 1.26 (-0.18)
Oncolytics' Reolysin Gets Orphan Drug Status Yet Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 1:38PM CST
Oncolytics' (ONCY) lead candidate Reolysin gets orphan drug status for primary peritoneal cancer.
CYTK: 7.95 (-0.02), ONCY: 1.01 (-0.15), CBM: 33.97 (+0.02), THRX: 19.64 (+0.08)
Premarket Gainers / Losers as of 9:10 em
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 8:13AM CST
BV: 6.41 (-2.67), AMRN: 1.69 (+0.15), PHMD: 1.98 (+0.15), BOBE: 46.36 (-13.28), NVGN: 3.36 (+0.85), EFUT: 4.70 (+0.57), TNET: 33.93 (-3.95), ATOS: 2.03 (+0.07), FAST: 39.82 (-1.28), W: 28.90 (+3.65), TIVO: 11.55 (+0.30), CYCC: 1.10 (-0.32), ANF: 20.27 (-3.72), CYTX: 1.14 (-0.06), AEO: 15.96 (+1.14), AMBA: 67.49 (+4.44), CRMD: 6.16 (+0.66), ONCY: 1.01 (-0.15), EXAS: 21.90 (+0.84), ATHM: 42.61 (+4.21), SOL: 1.43 (+0.08), VEEV: 25.72 (-6.97), OREX: 8.49 (+0.85), NURO: 1.78 (+0.03), ACHN: 11.63 (-0.51), CNDO: 3.23 (+0.44), SWHC: 14.34 (+1.29), IFON: 2.71 (+1.01)
Nasdaq stocks posting largest volume increases
AP - Tue Mar 03, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OREX: 8.49 (+0.85), GDEF: 10.38 (-0.02), WBB: 17.22 (-0.03), ONCY: 1.01 (-0.15), CYCC: 1.10 (-0.32), DRAM: 3.29 (+0.34), AXPW: 0.23 (-0.01), CMLS: 3.13 (-0.18), SQBK: 25.74 (+0.08), MITL: 9.56 (+0.20), TSRI: 5.07 (-0.21), MBLX: 0.97 (-0.08)
Most active Nasdaq-traded stocks
AP - Tue Mar 03, 5:06PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 16.59 (-0.22), OREX: 8.49 (+0.85), MU: 29.26 (-0.40), ONCY: 1.01 (-0.15), FB: 80.89 (+1.29), ARCP: 10.10 (+0.02), ZNGA: 2.39 (+0.04), MSFT: 43.05 (-0.23), INTC: 34.12 (+0.02), AAPL: 128.54 (-0.82), CSCO: 29.33 (-0.21)
Another Orphan Drug tag for Oncolytics' Reolysin
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 6:48AM CST
ONCY: 1.01 (-0.15)
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Primary Peritoneal Cancer
CNW Group - Tue Mar 03, 5:30AM CST
Oncolytics Biotech(®) Inc. ("Oncolytics"
(TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN(®), for the treatment of primary peritoneal cancers. The designation was granted on the basis of the Company's December 2014 application for an Orphan Drug Designation encompassing ovarian, fallopian tube and primary peritoneal cancers which are generally treated as one indication. On February 11, 2015, the Company announced that it had received Orphan Drug Designation for ovarian cancer and for cancers of the fallopian tube on March 2, 2015. ONCY: 1.01 (-0.15), ONC.TO: 1.26 (-0.18)
Oncolytics Biotech heads north on new Orphan Drug tag for Reolysin
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 12:44PM CST
ONCY: 1.01 (-0.15)
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Cancer of the Fallopian Tube
CNW Group - Mon Mar 02, 5:30AM CST
Oncolytics Biotech(®) Inc. ("Oncolytics"
(TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN(®), for the treatment of cancer of the fallopian tube. The designation was granted on the basis of the Company's December 2014 application for an Orphan Drug Designation encompassing ovarian, fallopian tube and primary peritoneal cancers which are generally treated as one indication. On February 11, 2015, the Company announced that it had received Orphan Drug Designation for ovarian cancer. ONCY: 1.01 (-0.15), ONC.TO: 1.26 (-0.18)
Oncolytics Biotech Completes Enrolment for Reolysin Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 19, 11:10AM CST
Oncolytics Biotech Inc. (ONCY) completed enrolment in a phase II study on its lead candidate, Reolysin, in patients suffering from advanced or metastatic colorectal cancer.
LCI: 62.28 (+0.01), ONCY: 1.01 (-0.15), SLXP: 157.13 (+0.63), SCMP: 14.82 (-0.15)
Traders smitten with tiny thinly-traded biotechs
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 9:44AM CST
GENE: 5.75 (+0.39), HTBX: 6.45 (-0.18), SGNL: 2.89 (+0.20), ROSG: 3.35 (unch), TTPH: 38.50 (-0.82), ONCY: 1.01 (-0.15), CLRX: 1.27 (-0.05), MELA: 1.82 (-0.01), AKAO: 10.42 (-0.33), WGBS: 4.80 (-0.05), EGRX: 37.72 (+1.03)
Oncolytics' Reolysin Gets Another Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 3:08PM CST
Oncolytics' (ONCY) lead candidate Reolysin gets orphan drug status for pancreatic cancer.
IPXL: 40.40 (+0.47), BMRN: 109.79 (+1.43), ONCY: 1.01 (-0.15), CBM: 33.97 (+0.02)
Oncolytics Bio completes enrollment in Canadian cancer trial
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 11:45AM CST
ONCY: 1.01 (-0.15)
Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Colorectal Cancer Study
CNW Group - Wed Feb 18, 5:30AM CST
Oncolytics Biotech(®) Inc. ("Oncolytics"
(TSX:ONC, NASDAQ:ONCY) today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN(® )in patients with advanced or metastatic colorectal cancer (IND 210). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario. ONCY: 1.01 (-0.15), ONC.TO: 1.26 (-0.18)
Oncolytics Bio's lead product an Orphan Drug for pancreatic cancer
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 1:04PM CST
ONCY: 1.01 (-0.15)
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Pancreatic Cancer
PR Newswire - Tue Feb 17, 5:30AM CST
Oncolytics Biotech® Inc. ("Oncolytics"
(TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer. ONCY: 1.01 (-0.15), ONC.TO: 1.26 (-0.18)
(0)
(0)Scroll down for more posts ▼